ATLAS: A phase II, open-label study of rucaparib in patients (pts) with locally advanced (unresectable) or metastatic urothelial carcinoma

被引：0
|
作者：
Chowdhury, S. [1 ,2 ]
Feyerabend, S. [3 ]
Loriot, Y. [4 ]
Necchi, A. [5 ]
Gupta, S. [6 ]
Josephs, D. H. [7 ]
Rodriguez-Vida, A. [8 ]
Srinivas, S. [9 ]
Zakharia, Y. [10 ,11 ]
Nepert, D. [12 ]
Wride, K. [13 ]
Thomas, D. [14 ]
Loehr, A. [15 ]
Simmons, A. D. [15 ]
Grivas, P. [16 ]
机构：
[1] Guys Hosp, Med Oncol, London, England
[2] Sarah Cannon Res Inst, London, England
[3] Studienpraxis Urol, Urol Oncol, Nurtingen, Germany
[4] Gustave Roussy, Dept Canc Med, Canc Campus, Villejuif, France
[5] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[6] Univ Utah, Huntsman Canc Inst, Genitourinary Oncol Program, Salt Lake City, UT USA
[7] Guys & St Thomas Hosp, Dept Med Oncol, London, England
[8] Hosp del Mar, Genitourinary Canc Unit, Barcelona, Spain
[9] Stanford Univ, Sch Med, Urol Oncol Clin, Stanford, CA 94305 USA
[10] Univ Iowa, Div Hematol, Iowa City, IA USA
[11] Holden Comprehens Canc Ctr, Iowa City, IA USA
[12] Clovis Oncol Inc, Clin Sci, Boulder, CO USA
[13] Clovis Oncol Inc, Biostat, Boulder, CO USA
[14] Clovis Oncol Inc, Clin Operat, Boulder, CO USA
[15] Clovis Oncol Inc, Translat Med, Boulder, CO USA
[16] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
928TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase II open-label study of sacituzumab govitecan in patients with previously treated locally advanced, recurrent, or metastatic cholangiocarcinoma (SIGNA).
    Kasi, Anup
    Al-Rajabi, Raed Moh'd Taiseer
    Li, Haoran
    Carroll, Erin
    Bradbury, Shannon
    Broxterman, Cassie
    Phadnis, Milind A.
    Baranda, Joaquina Celebre
    Sun, Weijing
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS651 - TPS651
  • [22] Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study
    Kang, Yoon-Koo
    George, Suzanne
    Jones, Robin L.
    Rutkowski, Piotr
    Shen, Lin
    Mir, Olivier
    Patel, Shreyaskumar
    Zhou, Yongjian
    von Mehren, Margaret
    Hohenberger, Peter
    Villalobos, Victor
    Brahmi, Mehdi
    Tap, William D.
    Trent, Jonathan
    Pantaleo, Maria A.
    Schoeffski, Patrick
    He, Kevin
    Hew, Paggy
    Newberry, Kate
    Roche, Maria
    Heinrich, Michael C.
    Bauer, Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28) : 3128 - +
  • [23] Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
    Powles, Thomas
    van der Heijden, Michiel S.
    Castellano, Daniel
    Galsky, Matthew D.
    Loriot, Yohann
    Petrylak, Daniel P.
    Ogawa, Osamu
    Park, Se Noon
    Lee, Jae-Lyun
    De Giorgi, Ugo
    Bogemann, Martin
    Bamias, Aristotelis
    Eigl, Bernhard J.
    Gurney, Howard
    Mukherjee, Som D.
    Fradet, Yves
    Skoneczna, Iwona
    Tsiatas, Marinos
    Novikov, Andrey
    Suarez, Cristina
    Fay, Andre P.
    Duran, Ignacio
    Necchi, Andrea
    Wildsmith, Sophie
    He, Philip
    Angra, Natasha
    Gupta, Ashok K.
    Levin, Wendy
    Bellmunt, Joaquim
    LANCET ONCOLOGY, 2020, 21 (12): : 1574 - 1588
  • [24] OPEN-LABEL PHASE II STUDY OF SORAFENIB plus DACARBAZINE IN PATIENTS WITH ADVANCED METASTATIC MELANOMA
    Gonzalez-Larriba, J. L.
    Guillem, V.
    Marmol, M.
    Valladares, M.
    Arrivi, A.
    Pastor, P.
    Garcia-Garcia, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 246 - 246
  • [25] A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)
    Powles, T. B.
    van der Heijden, M. S.
    Castellano Gauna, D.
    Loriot, Y.
    Galsky, M. D.
    Petrylak, D. P.
    Ogawa, O.
    Park, S. H.
    Necchi, A.
    Lee, J-L.
    De Giorgi, U.
    Boegemann, M.
    Bamias, A.
    Fay, A. P.
    Duran, I.
    Angra, N.
    Gupta, A. K.
    He, P.
    Levin, W.
    Bellmunt, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S550 - S551
  • [26] A single arm, multicenter, open label, phase II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract
    Wülfing, C
    Machiels, JP
    Richel, D
    Grimm, MO
    Treiber, U
    de Groot, M
    Beuzeboc, P
    Farrell, J
    Stone, NL
    Leopold, L
    El-Hariry, I
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 401S - 401S
  • [27] Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
    Sheng, Xinan
    Yan, Xieqiao
    Wang, Lin
    Shi, Yanxia
    Yao, Xin
    Luo, Hong
    Shi, Benkang
    Liu, Jiyan
    He, Zhisong
    Yu, Guohua
    Ying, Jianming
    Han, Weiqing
    Hu, Changlu
    Ling, Yun
    Chi, Zhihong
    Cui, Chuanliang
    Si, Lu
    Fang, Jianmin
    Zhou, Aiping
    Guo, Jun
    CLINICAL CANCER RESEARCH, 2021, 27 (01) : 43 - 51
  • [28] A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: Final results
    Gruenwald, V.
    Wilkens, L.
    Gebel, M.
    Greten, T. F.
    Kubicka, S.
    Ganser, A.
    Manns, M. P.
    Malek, N. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] Open-label phase II trial of everolimus monotherapy in patients with recurrent metastatic and/or unresectable renal cell carcinoma (RCC)
    Tannir, B.
    Hardikar, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST.
    Demetri, G. D.
    Heinrich, M. C.
    Chmielowski, B.
    Morgan, J. A.
    George, S.
    Bradley, R.
    Blackman, R. K.
    Teofilovici, F.
    Fletcher, J. A.
    Tap, W. D.
    von Mehren, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345